Jonathan Hand, MD
Infectious Disease · New Orleans, LANPI 1083938997
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,720 of the $9,879 with a category attached, or 68.0%. 7 manufacturers reported payments, led by Pfizer at 49.8% of the total. Reporting peaked in 2024 at $4,613 and has fallen 64.5% since, to $1,636 in 2025. Among infectious disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 17 payments — averaging $581.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- La Jolla Pharmaceutical Company$3K
- Astrazeneca UK Limited$2K
- AstraZeneca$120
- Sanofi$87
- Amgen$23
- plus $20 from 1 others
Across 180 payments — averaging $9192.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.1M
- Pfizer$437K
- Scynexis, Inc.$70K
- AstraZeneca$25K
- La Jolla Pharmaceutical Company$17K
- GSK$15K
- plus $12K from 1 others
What the payments were for
- Consulting fees$6,72068%
- Speaking & faculty fees$2,68027%
- Travel & lodging$671%
- Food & beverage$4124%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $4,924 |
| La Jolla Pharmaceutical Company | 5 | $2,885 |
| Astrazeneca UK Limited | 1 | $1,820 |
| AstraZeneca | 2 | $120 |
| Sanofi | 1 | $87 |
| Amgen | 1 | $23 |
| Johnson & Johnson | 2 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XACDURO$2,680
- PREVNAR 20$1,400
How this compares
$9,879 in reported general payments places this provider in the 90th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 114 | $449,784 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 32 | $117,114 |
| TivicayDolutegravir Sodium | 23 | $75,895 |
| JulucaDolutegravir/Rilpivirine | 15 | $65,519 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $45,168 |
| Daptomycin | 24 | $43,092 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $27,793 |
| VemlidyTenofovir Alafenamide | 14 | $17,849 |
| Etravirine | 14 | $9,687 |
| ErtapenemErtapenem Sodium | 35 | $7,222 |
| CeftriaxoneCeftriaxone Sodium | 47 | $4,912 |
| Meropenem | 12 | $2,220 |
| Cefepime Hcl | 11 | $2,037 |
| Lamivudine | 14 | $1,365 |
| Doxycycline Monohydrate | 33 | $1,234 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in New Orleans
- Eric EhrensingNew Orleans$97K
- Meredith ClementNew Orleans$93K
- Rebecca LillisNew Orleans$60K
- Stephanie TaylorNew Orleans$25K
- Edwin SwiatloNew Orleans$22K
- Markalain DeryNew Orleans$9K
- Julia Garcia-DiazNew Orleans$8K
- Obinna NneduNew Orleans$3K
- Katherine BaumgartenNew Orleans$3K
- George PankeyNew Orleans$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.